Cargando…

Only peak thyroglobulin concentration on day 1 and 3 of rhTSH-aided RAI adjuvant treatment has prognostic implications in differentiated thyroid cancer

OBJECTIVE: In patients with differentiated thyroid carcinoma (DTC), serum thyroglobulin levels measured at the time of remnant ablation after thyroid hormone withdrawal were shown to have prognostic value for disease-free status. We sought to evaluate serial thyroglobulin measurements at the time of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ledwon, Aleksandra, Paliczka-Cieślik, Ewa, Syguła, Aleksandra, Olczyk, Tomasz, Kropińska, Aleksandra, Kotecka-Blicharz, Agnieszka, Hasse-Lazar, Kornelia, Kluczewska-Gałka, Aneta, Jarząb, Barbara, Handkiewicz-Junak, Daria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494717/ https://www.ncbi.nlm.nih.gov/pubmed/34363597 http://dx.doi.org/10.1007/s12149-021-01663-y

Ejemplares similares

The assessment of side effects of tyrosine kinase inhibitors (TKI) applied in patients with advanced thyroid cancer (TC) - one centre experience
por: Krajewska, Jolanta, et al.
Publicado: (2013)

Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
por: Kukulska, Aleksandra, et al.
Publicado: (2020)

13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2009)

Stereotactic radiotherapy is a useful treatment option for patients with medullary thyroid cancer
por: Kukulska, Aleksandra, et al.
Publicado: (2021)

Postoperative Radioiodine Treatment within 9 Months from Diagnosis Significantly Reduces the Risk of Relapse in Low-Risk Differentiated Thyroid Carcinoma
por: Krajewska, Jolanta, et al.
Publicado: (2019)

Effect of rhTSH on Lipids
por: Delitala, Alessandro P., et al.
Publicado: (2020)

Early Diagnosis of Low-Risk Papillary Thyroid Cancer Results Rather in Overtreatment Than a Better Survival
por: Krajewska, Jolanta, et al.
Publicado: (2020)

TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma
por: Rusinek, Dagmara, et al.
Publicado: (2020)

The role of postoperative adjuvant radiotherapy in local recurrence risk in medullary thyroid carcinoma
por: Kukulska, Aleksandra, et al.
Publicado: (2019)

Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
por: Kukulska, Aleksandra, et al.
Publicado: (2010)

Differences in Gene Expression Profile of Primary Tumors in Metastatic and Non-Metastatic Papillary Thyroid Carcinoma—Do They Exist?
por: Szpak-Ulczok, Sylwia, et al.
Publicado: (2020)

Radioiodine therapy under rhTSH for follicular thyroid carcinoma with sellar metastasis and non-rising TSH
por: Taywade, Sameer Kamalakar, et al.
Publicado: (2016)

Comparison of clinical examination with orbital MRI evaluation in patients with thyroid orbitopathy - do we need imaging and when?
por: Król, Aleksandra, et al.
Publicado: (2013)

Comparing the effectiveness of stimulation using rhTSH and thyroid hormone withdrawal in the treatment of thyroid cancer
por: Kowalska, Aldona
Publicado: (2015)

Familial longevity is associated with lower baseline bone turnover but not differences in bone turnover in response to rhTSH
por: Zutinic, Ana, et al.
Publicado: (2021)

Determining the frequency of thyroid parameter measurements following rhTSH administration in a healthy, older population
por: Zutinic, Ana, et al.
Publicado: (2021)

Presentation of points of general discussion and voting among the speakers of the European Thyroid Association-Cancer Research Network (ETA-CRN) meeting in Lisbon, 2009, entitled ”European comments to ATA medullary thyroid cancer guidelines”
por: Jarząb, Barbara, et al.
Publicado: (2013)

Bone Markers Are Diminished in Offspring of Long-Lived Families Compared With Matched Controls, but Respond Equally to T3 and rhTSH
por: Zutinic, Anna, et al.
Publicado: (2021)

Ability of the rhTSH stimulation test to predict relapse in patients with differentiated thyroid carcinoma, after long-term follow-up
por: MARCELINO, MAFALDA, et al.
Publicado: (2015)

Primary Cilia Mediate TSH-Regulated Thyroglobulin Endocytic Pathways
por: Lee, Junguee, et al.
Publicado: (2021)

Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients
por: Rusinek, Dagmara, et al.
Publicado: (2018)

A Sensitive Tg Assay or rhTSH Stimulated Tg: What's the Best in the Long-Term Follow-Up of Patients with Differentiated Thyroid Carcinoma?
por: Persoon, Adrienne C.M., et al.
Publicado: (2007)

rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis
por: Ma, Chao, et al.
Publicado: (2013)

Poly (lactic-co-glycolic acid)-encapsulated iodine-131 nanoparticles fabricated with rhTSH induce apoptosis and immobilization of thyroid cancer cells
por: Fan, Yongzeng, et al.
Publicado: (2023)

Changes in TSH, T4, T3 and Thyroglobulin Levels throughout Total Thyroidectomy
por: Senese, Nora, et al.
Publicado: (2022)

The diagnostic and predictive accuracy of thyroglobulin to TSH ratio and TSH to thyroglobulin ratio in detecting differentiated thyroid carcinoma in normothyroid patients with thyroid nodules: A retrospective cohort study and systematic review of the literature
por: Karvounis, Evangelos, et al.
Publicado: (2021)

Can the basal serum thyroglobulin level be used to predict the recombinant human TSH-stimulated thyroglobulin level in differentiated patients with thyroid cancer?
por: Jeong, Eugene, et al.
Publicado: (2019)

(131)I thyroid activity and committed dose assessment among family members of patients treated with radioactive iodine
por: Brudecki, K., et al.
Publicado: (2020)

The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer
por: Kowalska, Aldona, et al.
Publicado: (2015)

Canonical TSH Regulation of Cathepsin-Mediated Thyroglobulin Processing in the Thyroid Gland of Male Mice Requires Taar1 Expression
por: Qatato, Maria, et al.
Publicado: (2018)

Heterogeneity of the Clinical Presentation of the MEN1 LRG_509 c.781C>T (p.Leu261Phe) Variant Within a Three-Generation Family
por: Gilis-Januszewska, Aleksandra, et al.
Publicado: (2021)

A novel 5′-hydroxyl dinucleotide hydrolase activity for the DXO/Rai1 family of enzymes
por: Doamekpor, Selom K, et al.
Publicado: (2020)

Factors Modifying Outcome After MIBG Therapy in Children With Neuroblastoma—A National Retrospective Study
por: Ussowicz, Marek, et al.
Publicado: (2021)

Utility of recombinant human TSH stimulation test in the follow-up of patients with differentiated thyroid cancer depending on basal thyroglobulin results
por: Sandúa, Amaia, et al.
Publicado: (2020)

Correction to ‘A novel 5′-hydroxyl dinucleotide hydrolase activity for the DXO/Rai1 family of enzymes’
por: Doamekpor, Selom K, et al.
Publicado: (2021)

Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma – Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015
por: Czarniecka, Agnieszka, et al.
Publicado: (2021)

Recombinant human TSH stimulated thyroglobulin levels at remnant ablation predict structural incomplete response to treatment in patients with differentiated thyroid cancer
por: Ha, Jeonghoon, et al.
Publicado: (2017)

Lack of TSH stimulation in patients with differentiated thyroid cancer – possible causes
por: Gut, Paweł, et al.
Publicado: (2012)

Role of Assistive Robots in the Care of Older People: Survey Study Among Medical and Nursing Students
por: Łukasik, Sylwia, et al.
Publicado: (2020)

TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy
por: Siderova, Mira, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jr038rfg6tfeeak3f4qd395nmj